AGMB-447
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout AGMB-447
AGMB-447 is a phase 1 stage product being developed by Agomab Therapeutics for IPF. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06181370. Target conditions include IPF.
Hype Score Breakdown
Clinical
6
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06181370 | Phase 1 | Recruiting |
Competing Products
9 competing products in IPF
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LTI-03 + Placebo | Rein Therapeutics | Phase 2 | 32 |
| Saracatinab + Placebo | AstraZeneca | Phase 1/2 | 36 |
| BMS-986278 + Pirfenidone | Bristol Myers Squibb | Phase 1 | 29 |
| HSK44459 | Haisco Pharmaceutical Group | Phase 2 | 42 |
| BG00011 + Placebo | Biogen | Phase 2 | 32 |
| TD-1058 + Placebo | Theravance Biopharma | Phase 1 | 15 |
| MNKD-201(Nintenadib DPI) + Placebo | MannKind Corp | Phase 1 | 30 |
| PIPE-791 | Contineum Therapeutics | Phase 1 | 23 |
| AP02 + Placebo | Avalyn Pharmaceuticals | Phase 2 | 32 |